RxDoctor Payments Data

Mariam Hasan, MD

Hospitalist · Milpitas, CANPI 1851604847

Payments from drug & device makers

$2,535in general payments, 2019–2025

Across 59 payments — averaging $42.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$963
  • Merz North America, Inc.$487
  • Lilly USA, LLC$336
  • Almatica Pharma LLC$124
  • Phathom Pharmaceuticals, Inc.$104
  • Novo Nordisk$103
  • plus $419 from 13 others

What the payments were for

  • Consulting fees$96338%
  • Food & beverage$1,57262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,535 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$19,118
Medicare patients
38
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$56,464
OzempicSemaglutide20$22,730
MounjaroTirzepatide15$20,166
JanuviaSitagliptin Phosphate21$18,680
JardianceEmpagliflozin17$17,939
MyrbetriqMirabegron17$7,556
FarxigaDapagliflozin Propanediol13$7,500
Breo ElliptaFluticasone/Vilanterol15$5,507
Ranolazine ErRanolazine13$3,165
Atorvastatin Calcium234$2,642
Albuterol Sulfate HfaAlbuterol Sulfate85$2,611
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,102
Metformin Hcl193$1,665
Amlodipine Besylate266$1,515
Metoprolol Succinate96$1,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$56,46485 claims
Novo NordiskOzempic$103$22,73020 claims
Lilly USA, LLCMounjaro$336$20,16615 claims
MerckJanuvia$18$18,68021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Milpitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →